SLNO Stock Price, Soleno Therapeutics Inc Quote, Chart

Market Summary

USD46.12+0.46

Delayed

1.01%

SLNO Alerts

1 major insider sales recently.

SLNO Stock Price

View Fullscreen

SLNO RSI Chart

SLNO Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-29.62

Price/Sales (Trailing)

1.1K

EV/EBITDA

-156.67

Price/Free Cashflow

-50.13

SLNO Price/Sales (Trailing)

SLNO Profitability

Operating Margin

26.92%

EBT Margin

-816.18%

Return on Equity

-36.29%

Return on Assets

-30.82%

Free Cashflow Yield

-1.99%

SLNO Fundamentals

SLNO Revenue

Revenue (TTM)

1.5M

SLNO Earnings

Earnings (TTM)

-52.0M

Earnings Growth (Yr)

-156.08%

Earnings Growth (Qtr)

-89.43%

Breaking Down SLNO Revenue

Last 7 days

2.5%

Last 30 days

21.7%

Last 90 days

-2.5%

Trailing 12 Months

954.2%

How does SLNO drawdown profile look like?

SLNO Financial Health

Current Ratio

11.23

SLNO Investor Care

Shares Dilution (1Y)

309.01%

Diluted EPS (TTM)

-2.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2017	0	0	0	0
2016	812.6K	1.0M	1.2M	1.5M
2015	2.3M	1.7M	1.0M	387.6K
2013	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Soleno Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	vivo opportunity, llc	sold	-15,851,600	45.13	-351,242	-
Apr 29, 2024	vivo opportunity, llc	sold	-35,850,000	47.8	-750,000	-
Apr 01, 2024	anish bhatnagar	sold	-784,645	41.3406	-18,980	chief executive officer
Apr 01, 2024	yen kristen	sold	-91,693	41.3407	-2,218	see remarks
Apr 01, 2024	mackaness james h	sold	-213,937	41.3406	-5,175	chief financial officer
Apr 01, 2024	hirano patricia c	sold	-91,693	41.3407	-2,218	see remarks
Jan 25, 2024	yen kristen	sold	-19,175	48.3	-397	see remarks
Jan 25, 2024	hirano patricia c	sold	-40,185	48.3	-832	see remarks
Jan 25, 2024	anish bhatnagar	sold	-122,054	48.3	-2,527	chief executive officer
Jan 08, 2024	mario ernest	gifted	-	-	-3,523	-

Which funds bought or sold SLNO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	reduced	-4.21	442,310	24,199,600	2.65%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-67.36	-1,194,540	635,066	-%
May 16, 2024	AWM Investment Company, Inc.	sold off	-100	-805,000	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	33.8	175,249	589,784	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	540	112,162	131,482	-%
May 15, 2024	MAPLELANE CAPITAL, LLC	unchanged	-	63,751	1,070,000	0.03%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	sold off	-100	-243,834	-	-%
May 15, 2024	HighVista Strategies LLC	new	-	446,318	446,318	0.16%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-57.81	-126,772,000	103,164,000	5.89%
May 15, 2024	SAMLYN CAPITAL, LLC	reduced	-27.45	-2,776,450	9,370,080	0.16%

Are Funds Buying or Selling SLNO?

Are funds buying SLNO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SLNO

No. of Funds

SLNO Alerts

1 major insider sales recently.

Unveiling Soleno Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 01, 2024	vivo opportunity fund holdings, l.p.	22.5%	7,316,851	SC 13D/A
Feb 14, 2024	commodore capital lp	2.3%	7e+05	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	3,068,031	SC 13G/A
Feb 13, 2024	janus henderson group plc	8.3%	2,523,897	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	5.99%	1,826,814	SC 13G/A
Oct 23, 2023	perceptive advisors llc	10.1%	3,074,542	SC 13D/A
Oct 16, 2023	carlyle group inc.	9.99%	2,893,615	SC 13D/A
Oct 12, 2023	commodore capital lp	6.0%	885,741	SC 13G
Oct 12, 2023	adage capital partners gp, l.l.c.	8.69%	1,327,000	SC 13G
Oct 11, 2023	vivo opportunity fund holdings, l.p.	30.5%	8,418,093	SC 13D/A

Recent SEC filings of Soleno Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 06, 2024	424B5	Prospectus Filed
May 02, 2024	424B5	Prospectus Filed
May 01, 2024	4	Insider Trading
May 01, 2024	SC 13D/A	13D - Major Acquisition
Apr 30, 2024	3	Insider Trading
Apr 30, 2024	3	Insider Trading
Apr 29, 2024	8-K	Current Report

Peers (Alternatives to Soleno Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Soleno Therapeutics Inc News

Latest updates

Soleno Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2013Q4	2013Q3
Revenue	-97.0%	4,000	134,500	265,000	283,788	329,000	388,000	447,000	21,555	247,000	97,000	-	-	-
Cost Of Revenue	-100.0%	-	42,000	209,000	410,306	399,000	51,000	461,000	256,683	56,000	22,000	18,000	-	-
Gross Profit	100.0%	-	-41,000	56,000	67,982	-70,000	-49,000	-14,000	-15,211	191,000	75,000	4,000	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-1,000	-	-	1,000	-	571,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.6%	169	181	64.00	31.00	20.00	26.00	32.00	37.00	43.00	36.00	43.00	49.00	57.00	65.00	72.00	79.00	32.00	38.00	29.00	34.00	39.00
Current Assets	-11.8%	151	171	54.00	20.00	9.00	16.00	21.00	25.00	30.00	22.00	29.00	35.00	43.00	50.00	56.00	63.00	16.00	21.00	12.00	17.00	21.00
Cash Equivalents	-74.8%	43.00	170	52.00	19.00	8.00	15.00	20.00	24.00	29.00	21.00	28.00	34.00	42.00	49.00	56.00	62.00	15.00	21.00	11.00	16.00	19.00
Net PPE	125.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	9.8%	25.00	23.00	40.00	19.00	17.00	16.00	17.00	17.00	16.00	18.00	22.00	21.00	19.00	19.00	24.00	23.00	23.00	23.00	14.00	20.00	15.00
Current Liabilities	17.0%	13.00	12.00	29.00	9.00	8.00	7.00	7.00	7.00	7.00	8.00	9.00	8.00	10.00	9.00	8.00	8.00	7.00	5.00	3.00	3.00	2.00
Shareholder's Equity	-9.0%	143	158	23.00	12.00	3.00	10.00	15.00	20.00	26.00	18.00	20.00	27.00	38.00	46.00	48.00	56.00	9.00	15.00	15.00	14.00	24.00
Retained Earnings	-7.7%	-297	-276	-265	-254	-245	-237	-231	-225	-219	-213	-210	-202	-191	-182	-179	-171	-163	-157	-143	-144	-134
Additional Paid-In Capital	1.7%	441	434	288	267	248	248	247	246	245	231	231	230	229	228	228	227	173	173	158	158	158
Accumulated Depreciation	-100.0%	-	0.00	-	-	-	0.00	-	-	-	0.00	-	-	-	0.00	-	-	-	0.00	-	-	-
Shares Outstanding	5.2%	33.00	32.00	15.00	9.00	8.00	8.00	8.00	9.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	33.00	-	-	-	8.00	-	-	-	61.00	-	-	-	98.00	-	-	-	28.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-97.2%	-12,500	-6,340	-6,306	-5,594	-6,700	-5,143	-4,656	-4,620	-6,362	-6,863	-5,406	-8,013	-7,488	-6,867	-6,164	-6,534	-5,659	-5,076	-4,719	-3,893	-3,687
Share Based Compensation	237.6%	6,445	1,909	2,201	1,204	631	632	683	571	644	418	906	857	1,095	393	374	341	392	204	153	220	248
Cashflow From Investing	-Infinity%	-115,244	-	-	-	-	-6.00	-	-	-	-13.00	-5.00	-	-4.00	-4.00	-	-	-	103	441	-6.00	-10.00
Cashflow From Financing	-99.2%	938	123,558	39,401	17,060	-	-	342	-282	14,032	-5.00	-	2.00	-125	-42.00	-195	53,963	-4.00	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SLNO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 14,602	$ 5,316
General and administrative	8,472	2,854
Change in fair value of contingent consideration	401	299
Total operating expenses	23,475	8,469
Operating loss	(23,475)	(8,469)
Other income, net
Interest income, net	2,077	113
Total other income, net	2,077	113
Net loss	(21,398)	(8,356)
Other comprehensive income (loss)
Net unrealized loss on marketable securities	(105)	0
Foreign currency translation adjustment	(1)	16
Total comprehensive loss	$ (21,504)	$ (8,340)
Net loss per common share basic	$ (0.59)	$ (0.88)
Net loss per common share diluted	$ (0.59)	$ (0.88)
Weighted-average common shares outstanding used to calculate basic net loss per common share	36,208,371	9,447,350
Weighted-average common shares outstanding used to calculate diluted net loss per common share	36,208,371	9,447,350

SLNO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 42,847	$ 169,681
Short-term investments	106,780
Prepaid expenses and other current assets	1,596	1,677
Total current assets	151,223	171,358
Long-term assets
Property and equipment, net	27	12
Operating lease right-of-use assets	338	407
Intangible assets, net	8,263	8,749
Long-term investments	8,821
Other long-term assets	165	165
Total assets	168,837	180,691
Current liabilities
Accounts payable	8,022	3,149
Accrued compensation	1,226	3,135
Accrued clinical trial site costs	2,395	3,393
Operating lease liabilities	310	273
Other current liabilities	1,511	1,555
Total current liabilities	13,464	11,505
Long-term liabilities
Contingent liability for Essentialis purchase price	11,950	11,549
Long-term lease liabilities	37	130
Total liabilities	25,451	23,184
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 33,337,079 and 31,678,159 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	33	32
Additional paid-in-capital	441,267	433,885
Accumulated other comprehensive loss	(106)
Accumulated deficit	(297,808)	(276,410)
Total stockholders’ equity	143,386	157,507
Total liabilities and stockholders’ equity	$ 168,837	$ 180,691

About Soleno Therapeutics Inc

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

CEO	Dr. Anish Bhatnagar M.D.
WEBSITE	https://soleno.life
INDUSTRY	Biotechnology
EMPLOYEES	25

Soleno Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Soleno Therapeutics Inc? What does SLNO stand for in stocks?

SLNO is the stock ticker symbol of Soleno Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Soleno Therapeutics Inc (SLNO)?

As of Fri May 17 2024, market cap of Soleno Therapeutics Inc is 1.54 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLNO stock?

You can check SLNO's fair value in chart for subscribers.

What is the fair value of SLNO stock?

You can check SLNO's fair value in chart for subscribers. The fair value of Soleno Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Soleno Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SLNO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Soleno Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SLNO is over valued or under valued. Whether Soleno Therapeutics Inc is cheap or expensive depends on the assumptions which impact Soleno Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLNO.

What is Soleno Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SLNO's PE ratio (Price to Earnings) is -29.62 and Price to Sales (PS) ratio is 1.1 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLNO PE ratio will change depending on the future growth rate expectations of investors.